about
A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or LymphomasAcalabrutinib With Alternating Cycles of Bendamustine / Rituximab and Cytarabine / Rituximab for Untreated Mantle Cell LymphomaThe Efficacy of Bendamustine, Gemcytabine, Dexamethasone (BGD) Salvage Chemotherapy With Autologous Stem Cell Transplantation (ASCT) Consolidation in Advanced Classical Hodgkin Lymphoma Patients Not Responding to ABVD TherapyBendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic LeukemiaSyB C-0501(Oral Bendamustine) in Patients With Advanced Solid TumorsStudy of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHLA Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular LymphomaBendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing RegimenStudy to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic LeukemiaBendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic LeukemiaBendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-Cell LymphomasStudy of Mantle Cell Lymphoma Treatment by RiBVDBendamustine Plus Rituximab Versus Fludarabine Plus RituximabRituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FILA Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin LymphomaStudy of Dasatinib and Bendamustine in Chronic Lymphocytic LeukemiaStudy of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaOpen Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian CancerTrial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory MalignancyGemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin LymphomaRituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell LymphomaSafety and Efficacy Study of Bendamustine to Treat Non-Hodgkin LymphomaA Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic LeukemiaPhase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MMBrief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular LymphomaOfatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's LymphomaCombined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular LymphomaZevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell LymphomaCombination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and LymphomaA Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma
P4844
Q61894366-062EB4BB-E95A-4005-920D-1BDF1C9EDD73Q61902398-D60B9DAE-423D-40A0-BCD6-F7BC73D5DB67Q61904908-76BC79DD-9C75-45B6-BFC1-30012D1884C7Q61906943-BCDB1620-E0CA-4E2C-81DD-7CE6A565858BQ61907380-B8BDABE8-948F-4340-9A3F-96A92E8AA361Q61907575-D317B0B4-CD28-48BE-8180-F9D04A815054Q61915294-7FE4C938-65AF-4ED6-8682-1231AF530E82Q61921400-F7DA436A-A0BF-4882-8819-70EFB2883774Q61936488-91764234-A20C-434E-BFE3-6F8FB67A44ECQ61938021-5FC775C4-4E9B-4F9D-B737-61392D7A184FQ61938484-8DC3B59D-B5DF-483F-8EE3-0D7F384EE65EQ61956396-8CCA2C8A-F145-45B7-8FA9-26D90CC0B342Q61956597-2159820D-024D-4F90-80DB-F1739855675FQ61957756-BA67DC28-7D04-400A-A34E-3B4EA765F3E1Q61965882-F36B78D0-7FA7-4AC5-939F-FAAC90047DB9Q61965993-B8C33E91-EAD7-4201-9A1E-1BA0CF66616DQ61966064-FE158DAE-3227-4AA5-AC38-01023746C1DFQ61970119-7FE70CDD-C769-4B42-95CE-43DEB94DB7A3Q61975040-CC040D60-6265-474A-A626-E82498567289Q61980434-3760B7B4-A82F-4663-8F32-6AE4035C98AEQ61980812-05854D45-92DB-4254-8D58-A549A8BA74C3Q61980889-AC803984-BA42-420F-8F41-3F4D67D057D1Q61981115-7310FCBC-2A50-48A9-8C04-E61E8F97DE53Q61981211-E1BA1B61-3E11-495E-9045-3C76D32479EEQ62035097-18136A6D-3E38-4A36-AFD8-054ADC6C6CF2Q63062817-4520A598-11DF-4AFC-9F8B-773FADD6666BQ63317039-EFA0157C-B2D2-4A65-BBBE-73B41FBA9E22Q63317542-B193FCA6-5CCA-4E83-911C-B2E6E46CEE46Q63318510-AA1F22B1-6BA8-4862-A770-991AA4406AE7Q63319426-14591773-6135-4D64-8020-451DE08C81DDQ63320238-A453CD30-5178-4ADD-AC69-A33AC2AEE14CQ63320395-C34600C9-013D-4188-B172-03704CE0A3B7Q63320711-F4DC888C-FB7D-44E8-B2AB-9655C26A8FE6Q63320747-34C95F87-16A6-4022-8087-866AA4BD07D2Q63321694-18E74509-A2B3-4683-B601-BCF33F945624Q63321785-001D55A6-C719-4C8F-9B89-E4C0B4D02BDAQ63322920-D5F41235-3747-4CB3-97C1-17CFAB3A5411Q63334246-601AC937-AB74-478F-B83C-11A0C3A0EBBAQ63337033-BC4FC9B5-C052-4268-A6AE-208E66439BD8Q63337549-85CA9D52-05EE-4EA1-AA44-7E794A29A207
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
bendamustine hydrochloride
@en
type
label
bendamustine hydrochloride
@en
prefLabel
bendamustine hydrochloride
@en
P486
P592
P661
P662
P2067
P231
P232
P233
CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O.Cl
P234
1S/C16H21Cl2N3O2.ClH/c1-20-14- ...... 1H,2-4,7-10H2,1H3,(H,22,23);1H
P235
ZHSKUOZOLHMKEA-UHFFFAOYSA-N
P2566
100.159.777
P274
C₁₆H₂₂Cl₃N₃O₂
P2840
P3117
DTXSID40188912
P3345
P486
D000069461
P4964
splash10-0bt9-0139000000-994923b2407f07554692
P592
CHEMBL1201734
P652
981Y8SX18M